Brief: Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety
16/10/2024 21:17
Oct 16 (Reuters) - Glaukos Corp GKOS.N :
* GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3
CONFIRMATORY TRIAL FOR EPIOXA™, ACHIEVING PRIMARY EFFICACY
ENDPOINT AND DEMONSTRATING FAVORABLE TOLERABILITY AND SAFETY
* GLAUKOS CORP - PHASE 3 TRIAL SUPPORTS NDA SUBMISSION BY
END OF
2024
Source text for Eikon: ID:nBw6zKwX5a
Further company coverage: GKOS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glaukos
See all newsGlaukos says late-stage eye disease treatment shows lasting benefits after single dose
Brief: Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes In Keratoconus
US RESEARCH ROUNDUP-Boeing, Twilio, WP Carey
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Glaukos Corp reports results for the quarter ended June 30 - Earnings Summary